Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 25s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Acute Coronary Syndrome A Review

Dr. Jahnu Bhoj Nagal[1], Dr. Manal Upadhyay[2], Dr. Swati Bang[3], Dr. Kavita Jain[4]

[1]Assistant professor, Department of Emergency medicine, JLN medical college, Ajmer Rajasthan.
Email ID: nagaljahnu@gmail.com
[2]GMERS, Medical college & hospital, Gotri, Vadodara, Gujrat.
Email ID: jiniupa@gmail.com
[3]Senior resident, Department of Anatomy ESIC medical college & hospital,Faridabad.
Email ID: drswatimaheshwari2906@gmail.com
[4]Professor & Head, Department of Emergency medicine, JLN medical college, Ajmer Rajasthan.
Email ID: drkavitajain15@gmail.com

Cite this paper as: Dr. Jahnu Bhoj Nagal, Dr. Manal Upadhyay, Dr. Swati Bang, Dr. Kavita Jain, (2025) Acute Coronary Syndrome A Review, *Journal of Neonatal Surgery*, 14 (25s), 973-978

ABSTRACT
According to studies, ACS is a set of conditions marked by a sudden decrease in BF to the heart, which may result in MI /UN-AN. These conditions are mostly attributable to obstructions in the CA, which may result from ruptured PQ/ TB. Therefore in our review we have discussed about its epidemiology, pathophysiology, diagnosis, pretreatment and treatment aspect for its better understanding....

Keywords: *MI , UN-AN, PQ, TB, ACS, CA*

1. INTRODUCTION

According to a study, acute coronary syndrome(ACS) is the primary cause of mortality is due to CAD-related reasons.[1] Its diagnosis can be made using electrocardiographic (ECG) indicators, particularly ST-segment elevation.[2] In emergency care, it is essential to adhere to scientific guidelines to administer the most appropriate treatment.[3] To ascertain the most effective therapies, it is imperative to evaluate the risks of hemorrhage and ischemic complications.[3] It basically includes 3 main manifestations STEMI, NSTEMI, and unstable angina(UN-AN).[4] The term is advantageous because it encapsulates the similarities in presentation and treatment among various disorders.[4] Thus, authors diagnostic preference has shifted toward “NSTEMI” as a result of the introduction of high-sensitivity troponin assays(hsTn-A), which are capable of detecting myocardial cell death due to myocardial ischemia(MIS) in the absence of a STEMI signal on the ECG.[4] Patients those who all were suffering from MIS may now be more precisely recognized due to more effective care and treatment.[5] When blood flow to the heart suddenly stops, it may cause a variety of symptoms and conditions known as AC syndrome (S).[6] These include UN-AN & MIS.[6] With high rates of morbidity & death documented in Western European hospitals, it poses the major problems among young generation worldwide.[7] In South Asian countries as well, the incidence of CV disease (D) is rising, and this problem is projected to worsen in the years to come.[8] Figure 1 is showing an obstruction in blood flow causing ACS



FIGURE 1: ACS[8]

EPIDEMIOLOGY

Despite substantial breakthroughs in the diagnosis & treatment of ACS, studies in past have shown that, CVD continues to be the leading cause of mortality worldwide, with 90% rate.[9,10] Addition to this, studies have shown that, IHS is also responsible for 12% of the annual disability-adjusted life years(DS-AD-LY) that are lost throughout the globe. [10–12] Thus, researches have shown significant differences around the globe for rate of revascularization & mortality after ACS.[13-15] In spite of this, the mortality rates in hospitals for patients with STEMI are worsened by shock & continue to be high, particularly in instances of cardiac arrest.[16]

PATHOPHYSIOLOGY

According to studies, it occur due to reduced blood flow to the region of the cardiac muscle which collectivey includes vasospasm(VP), plaque rupture(PR) & thrombus formation.[17,18] In this, studies have shown that, obstruction's location, size & duration differently influence the severity & results of ACS. [17,18]

1. Aetherosclerosis & PR

The cause of almost all AMI is mainly due to atherosclerotic plaque(PQ) formation.[19] Thus, the presence of vulnerable PQ suggests an elevated risk of future thrombosis(TMB).[19] According to astudy, these PQ have a big fat core with immune cells called macrophages, few smooth muscle cells in the outer layer, more tissue factor, and a weak, messy collagen structure in the outer layer. [20] The probability of future acute episodes in individuals with CAD is contingent upon the number of vulnerable PQ present. Therefore, variability in the frequency of recurrent events can be attributed to variations in the amount of these plaques. [19]

2. Thrombus formation(TB-F)

Study have shown that, the formation of TB, inhibits the blood flow & leads to ischemic effects, which is mainly caused by a PR.[21] This TB is made up of platelets, RBC, vasoconstrictors, and fibrin fibers(FF).[21] The stability and dissolvability of the TB are dictated by the FF. [21] Thus, according to a study the TB on the surface of a PQ might occur as a result of endothelial denudation(ED) or disruption of the PQ cap.[19] As opposed to superficial endothelial denudation, plaque

disruption(PD) is more often linked with major TB. [19] Coronary artery (CA) TB is caused by PR or erosion and finally may lead to ACS.[16] Thus, percutaneous coronary intervention outcomes(PCIO) and the patient's prognosis are impacted by the presence and duration of the TB. [16]

3. yocardial Dysfunction(M-DYF)

Study have reported that, MI demonstrates impaired relaxation & contractility, leading to hypokinetic or akinetic segments.[8] The extent of damage to the affected area can range from mild effects to severe outcomes such as heart failure(HF) or cardiogenic shock(CG-S). Therefore , CHF & inadequate cardiac output(CO) can lead to ischemic cardiomyopathy(IS-CMP).[8] MIS affecting the papillary muscle & can lead to mitral valve regurgitation(MVR), while abnormal wall motion may facilitate the development of mural TB.[8]

4. Myocardial Infarction (MI)

Study have shown that, myocardial necrosis(MN) & MI are the outcomes of decreased coronary blood flow(CBF).[8] In this, study reported that, the left ventricle may be the main site of involvement, while the right ventricle & atria may also be involved.[8] In addition to above, study have also concluded that, MI affects the whole thickness of the myocardium and causes abnormal Q waves on the ECG, which is an easy way to distinguish it from a nontransmural(NT) MI.[8] Furthermore, as we know already that, NT-MI results due to anomalies in the ST-segment and T-wave. [8]

5. Electrical dysfunction

Electrical dysfunction plays a important role. The lack of regular electrical activity leads to ischemic and necrotic cells. Alterations in conduction may indicate potential damage to the atrioventricular node, sinoatrial node, or particular conduction pathways. While others may be temporary, while others could persist over an extended period. [8]

DIAGNOSIS

The presence or absence of diagnostic ST-segment abnormalities on the 12-lead ECG serves as the initial critical decision point for a patient suspected of having ACS as shown in table 1.

	Women	Men <40 years	Men ≥40 years
Leads V_2-V_3	≥1·5 mm	≥2·5 mm	≥2 mm
Other leads	≥1 mm	≥1 mm	≥1 mm

TABLE 1: ST-ELEVATION MI[23]

Subsequently, we can examine the transformative impact of hsTn tests on the diagnostic approach for NSTEMI, encompassing UN-AN. Patients with a suspicion of ACS may gain from supplementary diagnostic techniques such as cardiac magnetic resonance imaging (MRI) or ECG to detect myocardial ischemia and other indicators of regional wall motion abnormalities. [24]

PHYSICAL EXAMINATION

There are several signs that indicate a significant risk, including tachycardia, a narrow pulse pressure, hypotension, and signs of congestion (such as pulmonary edema) or poor perfusion (such as chilly extremities).[25] A study showed that, patients with ACS are categorized according to the degree of clinical HF using the Killip classification. This classification ranges from Class I, which indicates no evidence of congestion, to Class IV, which indicates cardiogenic shock and thus, is a powerful predictor of mortality. [25] Mechanical problems from a heart attack usually lead to a quick drop in BF, along with a loud continuous heart sound on the left side of the chest if there is a sudden hole in the heart wall, a soft heart sound if there is a sudden leak in the mitral valve, and signs of fluid buildup around the heart if the outer wall of the heart is torn. These symptoms are typically present in the case of MI. [26]

EVALUATE SUSPECTED NSTEACS

The assessment of suspected ACS presents significant challenges due to the critical nature of timing, the possibility of serious underlying conditions, and the frequently ambiguous results observed during the initial evaluation. The ECG in non-ST elevation ACS may exhibit T-wave inversions. An increased level of circulating markers indicative of MN, including cardiac troponin I or T (cTnI or cTnT) and creatine kinase myocardial band (CK-MB), serves to distinguish NSTEMI from UN-AN. This differentiation is characterized by an initial rise, a peak, and a subsequent decline in the concentration of these biomarkers. [27]

High-sensitivity troponin assays

When it comes to the diagnosis of NSTEMI, study have shown that, cTn-A are recommended over other biomarkers, including CK-MB, since they are sensitive and relatively specific.[28] hsTn assays have better test features in comparison to traditional cTn assays, and they are more sensitive in the early stages of the disease, especially after the start of symptoms. Therefore, they have made it possible for the implementation of treatment algorithms that are referred to as quick rule-out algorithms. [27,28] These algorithms depend on the measurement of hsTn at the time of presentation (zero hours) and at a 2nd time (one to three hours later)[28] as shown in figure 2.



FIGURE 2: NON-ST ELEVATION ACS[23]

According to the recommendations established by the European Society of Cardiology in 2020, a 0-hour/1-hour algorithm is recommended.[28] The specific concentrations that are designated for the hsTn thresholds are determined by the test. [28]

PRE-TREATMENT

The term "pretreatment" means giving an antiplatelet medication(APM) before a coronary angiography to check the heart's blood vessels.[29] Since past 2020, the absence of clear proof from randomized controlled trials(RCT) supporting pretreatment has caused a reassessment of this approach for NSTE-ACS.[30] The current recommendations had significantly reduce the classification from class I level of evidence A to the revised class IIb level of evidence B.[29,30]

ANTI-PLATELET THERAPY (APT)

The existing guidelines suggest dual antiplatelet therapy (DAPT) showed a duration of 12 months of the type of stent implanted, unless contraindications are present. [29] In patients classified as HBR or non-HBR who do not present a high ischemic risk, DAPT may be administered for a duration of 3 to 6 months, followed by maintenance therapy.[29] This approach evaluates the equilibrium between reducing the risks of bleeding and ensuring adequate protection against thrombotic occurrences. It demonstrated an elevation in non-fatal ischemic events, specifically MI, following its cessation, while bleeding outcomes showed no significant differences.[31-33]

POLYPILL (PP)[29]

This strategy involves combining many guideline-recommended medications into a single formulation to enhance patient adherence and simplify the treatment regimen after ACS. The rationale is based on the challenges related to medication adherence, an essential element in the prevention of recurrent CV incidents. In post-acute coronary syndrome, medication adherence is often suboptimal. [34] Participants were randomly randomized to undergo the intervention including aspirin, ramipril, and atorvastatin, in contrast to conventional treatment.[34] Moreover, this cohort study demonstrated superior adherence towards the treatment.[34] The strategy also represents a notable progression in the management of patients with ACS.[34]

2. CONCLUSION

The assessment & mangement of ACS are continue advancing as it is cruical in developing countries. Thus, disparities based on sex, race, and ethnicity in recognition, management, and results should also be addressed in future studies as more considered efforts are requiered to understand it.

REFERENCES

[1] Fuster V, Kovacic JC. Acute coronary syndromes: pathology, diagnosis, genetics, prevention, and treatment. Circulation research. 2014 Jun 6;114(12):1847-51.

[2] Gach O, El HZ, Lancellotti P. Acute coronary syndrome. Revue medicale de Liege. 2018 May 1;73(5-6):243-50.

[3] Makki N, Brennan TM, Girotra S. Acute coronary syndrome. Journal of intensive care medicine. 2015 May;30(4):186-200.

[4] Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. American family physician. 2005 Jul 1;72(01):119-26.

[5] Braunwald E, Morrow DA. Unstable angina: is it time for a requiem?. Circulation. 2013 Jun 18;127(24):2452-7.

[6] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Glob Heart. 2018 Dec;13(4):305-338.

[7] Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome.[Updated 2023 Jul 10]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.

[8] Khurshid F, Farooq Z, Ayesha UA, Chaudhry S, Malik K. A Comprehensive Review of Acute Coronary Syndrome. Annals of Innovation in Medicine. 2023 Sep 22;1(2).

[9] Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 James, Spencer L et al.The Lancet, Volume 392, Issue 10159, 1789 – 1858.

[10] GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry. 2022 Feb 1;9(2):137-50.

[11] Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MS. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-639.

[12] Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MS. Heart disease and stroke statistics—2021 update. Circulation. 2021 Feb 23.

[13] Bueno H, Rossello X, Pocock SJ, Van de Werf F, Chin CT, Danchin N, Lee SW, Medina J, Huo Y. In-hospital coronary revascularization rates and post-discharge mortality risk in non–ST-segment elevation acute coronary syndrome. Journal of the American College of Cardiology. 2019 Sep 17;74(11):1454-61.

[14] Chandrashekhar Y, Alexander T, Mullasari A, Kumbhani DJ, Alam S, Alexanderson E, Bachani D, Wilhelmus Badenhorst JC, Baliga R, Bax JJ, Bhatt DL. Resource and infrastructure-appropriate management of ST-segment elevation myocardial infarction in low-and middle-income countries. Circulation. 2020 Jun 16;141(24):2004-25.

[15] Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, Diaz R, Avezum A, Oliveira GB, Wielgosz A, Parambath SR. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. The Lancet. 2020 Mar 7;395(10226):785-94.

[16] Omer MA, Tyler JM, Henry TD, Garberich R, Sharkey SW, Schmidt CW, Henry JT, Eckman P, Megaly M, Brilakis ES, Chavez I. Clinical characteristics and outcomes of STEMI patients with cardiogenic shock and cardiac arrest. Cardiovascular Interventions. 2020 May 25;13(10):1211-9.

[17] Yuan D, Chu J, Qian J, Lin H, Zhu G, Chen F, Liu X. New concepts on the pathophysiology of acute coronary syndrome. Reviews in Cardiovascular Medicine. 2023 Apr 17;24(4):112.

[18] Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome.[Updated 2023 Jul 10]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.

[19] Davies MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 1996 Oct 15;94(8):2013-20.

[20] Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar 1;83(3):361-6.

[21] Adnan G, Singh DP, Mahajan K. Coronary artery thrombus.2018

[22] Khurshid F, Farooq Z, Ayesha UA, Chaudhry S, Malik K. A Comprehensive Review of Acute Coronary Syndrome. Annals of Innovation in Medicine. 2023 Sep 22;1(2).

[23] Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. The Lancet. 2022 Apr 2;399(10332):1347-58.

[24] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). Circulation. 2018 Nov 13;138(20):e618-51.

[25] Killip III T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. The American journal of cardiology. 1967 Oct 1;20(4):457-64.

[26] Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, Price S, Schiele F, Tubaro M, Vranckx P, Zahger D. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care. 2020 Mar 1;9(2):183-97.

[27] Morrow DA. The fourth universal definition of myocardial infarction and the emerging importance of myocardial injury. Circulation. 2020 Jan 21;141(3):172-5.

[28] Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2021 Apr 7;42(14):1289-367.

[29] Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal: Acute Cardiovascular Care. 2024 Jan;13(1):55-161.

[30] Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2021 Apr 7;42(14):1289-367.

[31] Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH, Kim BO, Cho JH. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet. 2018 Mar 31;391(10127):1274-84.

[32] Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. Journal of the American College of Cardiology. 2023 Feb 14;81(6):537-52.

[33] Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA cardiology. 2022 Apr 1;7(4):407-17.

[34] Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I. Polypill strategy in secondary cardiovascular prevention. New England Journal of Medicine. 2022 Sep 15;387(11):967-77...

.